Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer

Circulating tumor DNA (ctDNA) dynamics in patients receiving capecitabine (CAPE) for early-stage triple-negative breast cancer

Natera's Environmental Policy

Nominating, Corporate Governance and Compliance Committee Charter

Code of Conduct

Circulating tumor DNA (ctDNA) serial analysis during progression on PD-1 blockade and later CTLA-4 rescue in patients with mismatch repair d

Circulating Tumor DNA in Stage III Colorectal Cancer, beyond Minimal Residual Disease Detection, toward Assessment of Adjuvant Therapy Effic

DENEB: Development of new criteria for curability after local excision of pathological T1 colorectal cancer using liquid biopsy

Signatera Breast Cancer Data Sheet

Signatera Patient Test Sample Report

Natera’s ESG commitment

Natera’s 2021 ESG & Social Responsibility Report

Natera's Cyber Security Policy Report

Natera's Quality Policy

Panorama Sample Report: High Risk

Panorama Sample Report: Low Risk

Circulating tumor DNA to detect minimal residual disease, response to adjuvant therapy and identify patients at high risk of recurrence

Tarazona N, Henriksen TV, Carbonell-Asins JA, et al. Oral presentation at: American Society of Clinical Oncologist; May 29-31, 2020; Virtual Meeting. Abstract 4009